ZFIN Image: Tonelotto et al., 2025, Fig. 5

Image

Figure Caption

Fig. 5 Ace-quininib (2) significantly reduces viability of OMM2.5 and SUIT2-007 cells. (A) A dose-dependent, significant decrease in OMM2.5 cell metabolic activity was observed following 96 h treatment with quininib (1) or ace-quininib (2) in comparison to 0.5 % DMSO treatment. One-way ANOVA with Dunnett's Test for Multiple Comparisons statistical analysis was performed; error bars represent mean ± SEM, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p < 0.0001. (N = 3–5). (B,C) IC50 values of quininib (1) (B) and ace-quininib (2) (C) in OMM2.5 cells following a 96 h treatment, as determined by metabolic activity assays. (D) A dose-dependent, significant decrease in SUIT2-007 cell metabolic activity was observed following 96 h treatment with ace-quininib (2) in comparison to 0.125 % DMSO treatment. One-way ANOVA with Dunnett's Test for Multiple Comparisons statistical analysis was performed; error bars represent mean ± SEM, ∗∗∗∗p < 0.0001 (N = 3). (E) IC50 value of ace-quininib (2) in SUIT2-007 cells following a 96 h treatment, as determined by metabolic activity assays.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Eur. J. Med. Chem.